Skip to main content

Table 2 Molecular mechanism of argon

From: Update of the organoprotective properties of xenon and argon: from bench to beside

Argon

Author

Effects revealed in human

Effects revealed in in vivo

Effects revealed in in vitro

Organprotection

Loetscher et al. [101], Fahlenkamp et al. [102], Ulbrich et al. [103]

  

Activation of MEK-ERK 1/2pathway

Brain

Abraini et al. [104]

 

Binding to GABAA-receptor

 

Brain

Fahlenkamp et al. [105]

 

↑ IL-1beta, ↑IL-6, ↑iNOS, ↑TGF-beta,

 

Brain

Zhuang et al. [106]

 

↑ Bcl-2

 

Brain

Ulbrich et al. [107]

  

Inhibition TLR 2/4

Brain

Ulbrich et al. [103]

  

↑ERK1/2,↑Heme-oxygenase-1

Brain

Zhao et al. [108]

  

PI3K Signaling, ↑Nrf2

Brain

  1. ↑ upregulation; ↓ downregulation; ≈ no changes, blockade; AMPA a-amino-3-hydroxy-5-methyl-4-isoxazolole propionate, kainate; Bcl-2 B cell lymphoma 2; GABAA receptor gamma-aminobutyric acid A receptor; LPS lipopolysaccharide; ERK1/2 extracellular signal-regulated kinases 1/2; MEK1/2 = MAPKK mitogen-activated protein kinase; mTOR mammalian target of rapamycin; Nrf2 nuclear factor (erythroid-derived 2)-like 3; TLR Toll-like receptor; NF-κB nuclear factor “kappa-light-chain-enhancer” of activated B cells